Literature DB >> 22257107

Failure to correct International Normalized Ratio and mortality among patients with warfarin-related major bleeding: an analysis of electronic health records.

J Menzin1, J Hoesche, M Friedman, C Nichols, G E Bergman, M Crowther, D Garcia, C Jones.   

Abstract

BACKGROUND: Delayed correction of blood clotting times as measured by the International Normalized Ratio (INR) is associated with adverse outcomes among certain patients with warfarin-related major bleeding. However, there are limited data on the association between INR correction and mortality.
OBJECTIVE: To assess factors associated with 30-day mortality and time to death in patients receiving fresh frozen plasma (FFP) for warfarin-associated major bleeding.
METHODS: A retrospective database analysis was undertaken with electronic health record data from a large integrated health system. Patients met the following criteria: major hemorrhage diagnosis; INR ≥ 2 on the day before or day of receipt of FFP; and prescription fill for warfarin within 90 days. INR correction (defined as INR ≤ 1.3) was evaluated at the last available test 1 day following the start of FFP administration. Kaplan-Meier curves and Cox proportional hazards models were constructed to assess mortality.
RESULTS: Four hundred and five patients met the selection criteria (mean age of 75 years, 54% male), and 67% remained uncorrected at 1 day following the start of FFP administration. Among all patients, 11% died within 30 days of hospital admission. An uncorrected INR was not associated with a higher risk of 30-day mortality for patients overall, but was statistically significant for the subgroup with intracranial hemorrhage (ICH) (adjusted odds ratio 2.55; 95% confidence interval 1.04-6.28).
CONCLUSIONS: Among the subgroup of major bleeding patients with warfarin-associated ICH, those not correcting to either INR ≤ 1.3 or INR ≤ 1.5 with the use of FFP have an increased rate of mortality at 30 days.
© 2012 International Society on Thrombosis and Haemostasis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22257107     DOI: 10.1111/j.1538-7836.2012.04636.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  11 in total

1.  Timing of INR reversal using fresh-frozen plasma in warfarin-associated intracerebral hemorrhage.

Authors:  Murtaza Akhter; Andrea Morotti; Abigail Sara Cohen; Yuchiao Chang; Alison M Ayres; Kristin Schwab; Anand Viswanathan; Mahmut Edip Gurol; Christopher David Anderson; Steven Mark Greenberg; Jonathan Rosand; Joshua Norkin Goldstein
Journal:  Intern Emerg Med       Date:  2017-06-01       Impact factor: 3.397

2.  Real world usage of PCC to "rapidly" correct warfarin induced coagulopathy.

Authors:  Peter Toth; Joost Jair van Veen; Kate Robinson; Rhona Murray Maclean; Kingsley Kevin Hampton; Stuart Laidlaw; Michael Makris
Journal:  Blood Transfus       Date:  2012-10-10       Impact factor: 3.443

3.  Guideline-concordant administration of prothrombin complex concentrate and vitamin K is associated with decreased mortality in patients with severe bleeding under vitamin K antagonist treatment (EPAHK study).

Authors:  Karim Tazarourte; Bruno Riou; Benjamin Tremey; Charles-Marc Samama; Eric Vicaut; Bernard Vigué
Journal:  Crit Care       Date:  2014-04-24       Impact factor: 9.097

4.  Use of prothrombin complex concentrate in warfarin anticoagulation reversal in the emergency department: a quality improvement study of administration delays.

Authors:  Simon Bordeleau; Julien Poitras; Danièle Marceau; Carolle Breton; Pierre Beaupré; Patrick M Archambault
Journal:  BMC Health Serv Res       Date:  2015-03-15       Impact factor: 2.655

5.  A preliminary review of warfarin toxicity in a tertiary hospital in Cape Town, South Africa.

Authors:  Annemarie Jacobs; Fatima Bassa; Eric H Decloedt
Journal:  Cardiovasc J Afr       Date:  2017-05-21       Impact factor: 1.167

6.  Compliance with pathology testing guidelines in Australian general practice: protocol for a secondary analysis of electronic health record data.

Authors:  Gorkem Sezgin; Andrew Georgiou; Rae-Anne Hardie; Ling Li; Lisa G Pont; Tony Badrick; Guilherme S Franco; Johanna I Westbrook; Natalie Rinehart; Adam McLeod; Christopher Pearce; Marianne Shearer; Robin Whyte; Elizabeth Deveny
Journal:  BMJ Open       Date:  2018-11-13       Impact factor: 2.692

Review 7.  Monitoring of hematological and hemostatic parameters in neurocritical care patients.

Authors:  Andrew M Naidech; Monisha A Kumar
Journal:  Neurocrit Care       Date:  2014-12       Impact factor: 3.210

8.  Should we test the prothrombin time in anticoagulated epistaxis patients?

Authors:  Michael B Soyka; David Holzmann
Journal:  Allergy Rhinol (Providence)       Date:  2013

9.  A French multicenter randomised trial comparing two dose-regimens of prothrombin complex concentrates in urgent anticoagulation reversal.

Authors:  Delphine Kerebel; Luc-Marie Joly; Didier Honnart; Jeannot Schmidt; Damien Galanaud; Claude Negrier; Friedrich Kursten; Pierre Coriat
Journal:  Crit Care       Date:  2013-01-10       Impact factor: 9.097

10.  Emergency intensive care unit pharmacist's intervention may reduce time to four-factor prothrombin complex concentrate administration: a retrospective study.

Authors:  Shoichi Imanaka; Tatsuro Kuwabara; Hiroto Ikeda; Yasufumi Miyake; Hiromi Enomoto; Tetsuya Sakamoto; Nobuhiro Yasuno
Journal:  J Pharm Health Care Sci       Date:  2020-04-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.